{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to withhold', 'bronchodilators according to their action duration, for example, withholding the last dose', 'of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours, withholding the', 'last dose of LABA for at least 12 hours, and withholding the last dose of LAMA for at', 'least 24 hours. This will be verified before performing the PEF measurements.', 'Schedule a site visit 2 weeks later (Week 8 3 days) and ask patient to come in at', 'approximately the same time of this visit.', '10.1.7 Visit 7 (Week 10 [+ 3 days])', 'Record all concomitant medication use; inquire about AEs/SAEs and background asthma', 'therapy tolerability', 'Measure vital signs (blood pressure, heart rate, respiratory rate, body temperature, weight,', 'height)', 'Assess the menstruation status', 'Administer ACQ-7', 'Measure exhaled nitric oxide', '-', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast', 'of >1 hour.', 'Perform spirometry', '-', 'Spirometry will be performed at approximately the same time of last visit after a wash', 'out period of bronchodilators according to their action duration, for example,', 'withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at', 'least 6 hours, withholding the last dose of LABA for at least 12 hours, and withholding', 'the last dose of LAMA for at least 24 hours. This will be verified before performing', 'the PEF measurements.', 'Download electronic diary/PEF meter and remind patient and their', 'parent(s)/caregiver(s)/legal guardian(s) to bring the device to the next visit', 'Call IVRS/IWRS to register visit and obtain treatment kit number', 'Dispense and administer IMP', '-', 'Patients will be monitored at the study site for a minimum of 30 minutes after the', 'injection.', '-', 'For those parent(s)/caregiver(s)/legal guardian(s) willing and trained to perform', 'home-administration of IMP-injection (see Section 8.1.3 for details):', 'Under the close supervision of the Investigator or delegate, parent(s)/caregiver(s)/legal', 'guardian(s) will perform the injection, including feedback on technique by the', 'Investigator or delegate. Assess that the training for IMP home administration is', \"documented in the patient's study file.\", 'Property of the Sanofi Group - strictly confidential', 'Page 86', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Remind parent(s)/caregiver(s)/legal guardian(s) to use salbutamol/albuterol or', 'levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct', 'parent(s)/caregiver(s)/legal guardian(s) to record usage in the electronic diary.', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to continue their stable', 'dose of ICS in combination with a second controller as used during the Screening Period', 'and instruct parent(s)/caregiver(s)/legal guardian(s) to record daily usage in the electronic', 'diary', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to withhold', 'bronchodilators according to their action duration, for example, withholding the last dose', 'of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours, withholding the', 'last dose of LABA for at least 12 hours, and withholding the last dose of LAMA for at', 'least 24 hours. This will be verified before performing the PEF measurements.', 'Schedule a site visit 2 weeks later (Week 12 3 days) and ask patient to come in at', 'approximately the same time of this visit.', '10.1.8 Visit 8 (Week 12 [+ 3 days])', 'Record all concomitant medication use; inquire about AEs/SAEs and background asthma', 'therapy tolerability', 'Measure vital signs (blood pressure, heart rate, respiratory rate, body temperature, weight,', 'height)', 'Administer ACQ-7', 'Administer all additional PROs:', 'PAQLQ(S)-IA, PRQLQ-IA, PACQLQ.', 'Administer HCRU', 'Measure exhaled nitric oxide', '-', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast', 'of > 1 hour.', 'Perform spirometry', '-', 'Spirometry will be performed at approximately the same time of last visit after a wash', 'out period of bronchodilators according to their action duration, for example,', 'withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at', 'least 6 hours, withholding the last dose of LABA for at least 12 hours, and withholding', 'the last dose of LAMA for at least 24 hours. This will be verified before performing', 'the PEF measurements.', '-', 'Post-bronchodilator FEV1 should be determined.', 'Obtain urine for urinalysis (dipstick)', 'Assess menstruation status and perform urine dipstick pregnancy test for female patients', 'of childbearing potential (who have commenced menstruating)', 'Perform blood sampling (prior to administration of IMP) for the following tests:', 'Property of the Sanofi Group - strictly confidential', 'Page 87', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}